| Patent application number | Description | Published |
|---|
| 20090098289 | Pig and Method for Applying Prophylactic Surface Treatments - The invention relates to method for forming at least one metal oxide on one or more interior surfaces of closed or partially closed fluid transport or processing systems. The method involves applying at least one metal compound to the interior surfaces to be treated using, for example, one or more traveling applicators, commonly known as “pigs.” Then, the at least one metal compound is converted to at least one metal oxide, such as by heating the surfaces. In some embodiments, the at least one metal oxide provides a protective metal oxide coating adhered to those surfaces. Embodiments of the present invention can be performed in situ on existing fluid processing or transport systems. | 04-16-2009 |
| 20100112378 | Methods For Providing Prophylactic Surface Treatment For Fluid Processing Systems And Components Thereof - In one embodiment, the invention relates to a method for creating a diffused thin film surface treatments on one or more interior surfaces of closed or partially closed fluid transport or processing systems providing improved surface prophylaxis against fouling. The method involves contacting the interior surfaces to be treated with a metal compound composition, and converting the metal compound composition to metal oxide for example by heating the surfaces to the desired temperature after all or a part of the system has been assembled. Embodiments of the present invention can be performed in situ on existing fluid processing or transport systems, which minimizes the disruption to the surface treatment created by welds, joints, flanges, and damage caused by or during the system assembly process. | 05-06-2010 |
| 20100159264 | COATINGS FOR METAL CASTING PARTS - The method is disclosed for coating or impregnating a metal tool with a metal oxide to render the metal part more resistant to liquid metal attack or micro-welds. The method includes the steps of applying a liquid metal carboxylate composition, or a solution thereof, to a substrate material, and exposing the substrate to an environment that will cause vaporization or dissipation of any excess carboxylic acids in the liquid metal carboxylate composition while the metal carboxylates are being converted to metal oxides. | 06-24-2010 |
| Patent application number | Description | Published |
|---|
| 20090289184 | METHOD FOR THE ANALYSIS OF TISSUE SECTIONS - The present invention relates to a method for the histologic classification of a tissue section. The method includes acquiring a mass spectrometric image and a light-optical image of the same tissue section (the optical image having a higher spatial resolution than the mass spectrometric image) and combining optical information on the structures of a subarea of the tissue section with mass spectrometric information on the subarea (the structures not being spatially resolved in the mass spectrometric image). | 11-26-2009 |
| 20100255531 | ANALYSIS OF SINGLE BIOLOGICAL CELLS - An analysis of type, state or other distinguishing features of individual cells from body fluids, smears or tissues includes the steps of depositing the cells, with a minimum possible overlap, on a mass spectrometric sample support, determining the coordinates of the cells, coating the sample support with a layer of small crystals of a matrix substance, positioning the cells, inside a mass spectrometer, according to their known coordinates with a movement device into the position of the laser focus, acquiring mass spectra of the individual cells with ionization of the cell components by matrix assisted laser desorption, and using the mass spectra for an analysis of type, state or other distinguishing features of the cells. | 10-07-2010 |
| 20110059554 | DETERMINING AN EXPRESSION STATUS OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN A BIOLOGICAL SAMPLE - A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2. | 03-10-2011 |
| Patent application number | Description | Published |
|---|
| 20100255531 | ANALYSIS OF SINGLE BIOLOGICAL CELLS - An analysis of type, state or other distinguishing features of individual cells from body fluids, smears or tissues includes the steps of depositing the cells, with a minimum possible overlap, on a mass spectrometric sample support, determining the coordinates of the cells, coating the sample support with a layer of small crystals of a matrix substance, positioning the cells, inside a mass spectrometer, according to their known coordinates with a movement device into the position of the laser focus, acquiring mass spectra of the individual cells with ionization of the cell components by matrix assisted laser desorption, and using the mass spectra for an analysis of type, state or other distinguishing features of the cells. | 10-07-2010 |
| 20110059554 | DETERMINING AN EXPRESSION STATUS OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN A BIOLOGICAL SAMPLE - A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2. | 03-10-2011 |
